Related Experiment Videos
Mn-DPDP in MR imaging of pancreatic adenocarcinoma: initial clinical experience
H B Gehl1, R Urhahn, K Bohndorf
1Department of Diagnostic Radiology, Technical University of Aachen, Germany.
Abstract:
Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate) (DPDP) was tested as a contrast agent for magnetic resonance imaging of pancreatic adenocarcinoma in 15 patients. At enhanced T1-weighted spin-echo (SE) and enhanced T1-weighted gradient-echo (GRE) imaging, statistically significant increases in signal-to-noise ratio (S/N) for the pancreas (21% and 92%, respectively) and contrast-to-noise ratio (C/N) (91% and 209%, respectively) were found. The C/N at enhanced T1-weighted SE imaging was superior to that at unenhanced imaging, including T2-weighted SE imaging (P = .001). Subjective image analysis showed that delineation of the pancreas and pancreatic tumors was clearly improved (P = .05) on enhanced T1-weighted SE and GRE images compared with on unenhanced T1- and T2-weighted images. The liver enhanced 19% at T1-weighted SE imaging and 90% at T1-weighted GRE imaging. There was a significantly higher S/N increase in hepatic parenchyma than in pancreatic tissue at enhanced T1-weighted GRE imaging (P = .0026) but not at enhanced T1-weighted SE imaging.
Insights
Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate) (DPDP) significantly improved MRI contrast for pancreatic adenocarcinoma. Enhanced imaging showed superior pancreas and tumor visualization compared to unenhanced scans.
Area of Science:
- Medical Imaging
- Oncology
- Radiology
Background:
- Pancreatic adenocarcinoma detection remains challenging.
- Improved contrast agents are needed for enhanced MRI visualization.
Purpose of the Study:
- To evaluate Manganese (II) N,N '-dipyridoxylethylenediamine-N,N '-diacetate 5,5 '-bis(phosphate) (DPDP) as an MRI contrast agent.
- To assess DPDP's efficacy in imaging pancreatic adenocarcinoma.
Main Methods:
- 15 patients with pancreatic adenocarcinoma underwent MRI.
- DPDP was administered as a contrast agent.
- Enhanced T1-weighted spin-echo (SE) and gradient-echo (GRE) imaging were compared with unenhanced sequences.
Main Results:
- Statistically significant increases in pancreas signal-to-noise ratio (S/N) and contrast-to-noise ratio (C/N) were observed with DPDP.
- DPDP enhanced T1-weighted SE imaging showed superior C/N compared to unenhanced imaging (P = .001).
- Subjective analysis confirmed improved delineation of the pancreas and tumors (P = .05).
Conclusions:
- DPDP is an effective MRI contrast agent for pancreatic adenocarcinoma.
- DPDP enhances visualization of pancreatic tumors, improving diagnostic accuracy.
- Further research into DPDP's hepatic enhancement characteristics is warranted.